VanEck has launched the VanEck Genomics and Healthcare Innovators UCITS ETF on the London Stock Exchange and the German Xetra Stock Exchange.
The new ETF allows investors to invest in a combination of genomics and digitalisation, two of the “most important” areas in developmental healthcare.
The ETF follows the MVIS Global Future Healthcare ESG Index, which tracks the performance of companies contributing to genetic or digital applications in healthcare.
Companies must generate at least half of their sales in a series of areas identified by VanEck:
• Health therapies based on the targeted modification of the genetic code of cells or using mRNA
• Technology platforms that enable the development of therapies for healthcare based on genetics
• Laboratory equipment or services used to test, code, or develop genetics-based health therapies
• Software to facilitate online medical consultations
• Online pharmacies
• Software for the management of medical practices and/or patient records
• Ambulatory medical IoT devices
The genomics industry, which targets prominent topics such as the treatment of cancer, ageing and congenital diseases, is still in the early stages of its development.
“Genetic treatments, which have once been considered experimental and expensive, are becoming more affordable and common,” said Martijn Rozemuller, CEO at VanEck Europe.
Rozemuller also noted the healthcare industry, which was lagging in adopting IT solutions before the pandemic, has seen a surge in digitalisation over the past two years.
“Face-to-face meetings with patients were no longer an option, and digital solutions were able to prove their everyday viability in the healthcare industry. So far, however, digital solutions are still far from widespread. We assume that there is still room for further growth,” he said.
The accumulating VanEck Genomics and Healthcare Innovators UCITS ETF has a total expense ratio of 0.35% and is rebalanced semi-annually.
© 2022 funds europe
